Using bacteria to clean the environment
In recent years, concerns have heightened about increasing amounts of drugs in the environment, particularly in water. While the impact of this environmental pollution is not well understood, some evidence indicates that these drugs may be entering the food chain. Researchers believe that most of the drugs that end up in fresh water first accumulate at wastewater treatment facilities. Therefore, there is a need to eliminate the drugs at these facilities.
Ashley Robinson, a senior biochemistry major at Hamline University who plans to start graduate school in the fall, started doing research in her sophomore year. She is presenting a poster at the 2021 ASBMB Annual Meeting on this topic, the third research project she has worked on with Betsy Martínez–Vaz.
The researchers’ goal was to find bacteria that break down metformin, a drug commonly used to treat diabetes in the U.S. and around the world. Little research has been done on the impact of pollution with metformin and its byproduct, guanylurea, which are not fully metabolized by humans and thus are excreted into wastewater systems. “We consider them to be emerging pollutants,” Robinson said.
Studies have demonstrated the potential for metformin to disrupt some hormones, she explained. The drug is considered an endocrine disruption agent in some small fishes, and guanylurea has been shown to interfere with the nitrogen cycle in soil. Little is known about its bioaccumulation potential.
“Can these molecules pass up the food chain?” Robinson said. “That is one concern that we have.”
The research team collected samples at a local wastewater treatment facility from several stages of the treatment process. The bacteria in the samples were then grown in the lab under limiting conditions, meaning the bacteria were not given all the nutrients they needed. In this case, their only source of nitrogen was metformin, so most of the bacteria that survived were species that could use metformin as a nitrogen source. The team then used metagenomics to identify the enzymes involved in the breakdown of guanylurea and its transformation product guanidine. They identified three enzymes: guanylurea hydrolase, carboxyguanidine deiminase and allophanate hydrolase.
Robinson and her colleagues are now working to identify the enzyme that breaks down metformin in the initial step that forms guanylurea. They hope the enzymes they find could be used to break down metformin and guanylurea at wastewater treatment facilities, keeping these pollutants out of freshwater systems.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition weekly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
Guiding grocery carts to shape healthy habits
Robert “Nate” Helsley will receive the Walter A. Shaw Young Investigator in Lipid Research Award at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.
Quantifying how proteins in microbe and host interact
“To develop better vaccines, we need new methods and a better understanding of the antibody responses that develop in immune individuals,” author Johan Malmström said.
Leading the charge for gender equity
Nicole Woitowich will receive the ASBMB Emerging Leadership Award at the 2025 ASBMB Annual meeting, April 12–15 in Chicago.
CRISPR gene editing: Moving closer to home
With the first medical therapy approved, there’s a lot going on in the genome editing field, including the discovery of CRISPR-like DNA-snippers called Fanzors in an odd menagerie of eukaryotic critters.
Finding a missing piece for neurodegenerative disease research
Ursula Jakob and a team at the University of Michigan have found that the molecule polyphosphate could be what scientists call the “mystery density” inside fibrils associated with Alzheimer’s, Parkinson’s and related conditions.
From the journals: JLR
Enzymes as a therapeutic target for liver disease. Role of AMPK in chronic liver disease Zebrafish as a model for retinal dysfunction. Read about the recent JLR papers on these topics.